ABT vs PARA · P/E 25, rev $44.33B vs rev $5.0M
Abbott Laboratories (ABT) versus PARA (PARA) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
PARA (PARA) common stock.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported PARA revenue for 2026-06-30 was $5.0M. Net income was -$13.4M. Revenue was up 84.3% from 2026-03-31 to 2026-06-30. PARA currently screens at market cap $0.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. PARA currently screens at market cap $0.
Not investment advice. Open the ABT and PARA stock pages for the full models.
Not investment advice.